By Abbas Nazil
A medical editorial highlights that commonly used asthma and COPD inhalers are a significant but often overlooked source of carbon emissions within healthcare systems.
The article argues that pressurised metered dose inhalers contribute substantially to greenhouse gas emissions due to their use of hydrofluorocarbon propellants.
It warns that healthcare systems must balance effective respiratory treatment with environmental responsibility as climate change pressures increase globally.
Evidence cited in the report shows that healthcare contributes around seven percent of total emissions in some high-income countries such as Australia.
Within that share, inhaler devices are responsible for roughly thirteen percent of healthcare-related emissions due to their full life cycle impact.
The life cycle includes raw material extraction, manufacturing, distribution, daily use, and eventual disposal of inhaler devices.
A key environmental concern is the release of hydrofluorocarbons during inhaler use, which have a global warming potential far higher than carbon dioxide.
Some inhaler propellants such as HFC-134a and HFC-227ea are described as thousands of times more potent than carbon dioxide equivalents.
The editorial explains that continued reliance on these devices could significantly increase emissions as asthma and respiratory diseases become more common.
It notes that policy efforts such as the Kigali Amendment aim to gradually phase down high-impact hydrofluorocarbon gases globally.
However, it stresses that policy alone is insufficient without changes in clinical prescribing behaviour and healthcare delivery systems.
One major recommendation is increased use of dry powder inhalers and soft mist inhalers, which do not rely on greenhouse gas propellants.
These alternatives are described as having significantly lower carbon footprints while maintaining similar clinical effectiveness for many patients.
Studies referenced indicate that switching from pressurised inhalers to alternative devices could reduce emissions by more than sixty percent in some settings.
The article also highlights ongoing research into lower-impact propellants such as HFA-152a and HFO-1234ze to reduce emissions from existing device types.
Another important issue raised is the environmental burden of single-use plastic components in inhaler packaging and accessories.
Improper disposal of inhalers in landfills is said to prolong emissions due to residual gas leakage over time.
Recycling programmes such as national return schemes are presented as effective strategies to reduce environmental harm from discarded inhalers.
The editorial further emphasises that prescribing behaviour plays a major role in emission reduction through appropriate diagnosis and treatment selection.
Overuse of short-acting beta agonist relievers is identified as a key contributor to unnecessary inhaler consumption and emissions.
Better use of preventer inhaled corticosteroids is shown to reduce hospital admissions and overall inhaler demand in respiratory patients.
Clinical education is recommended to improve awareness among doctors and patients regarding environmentally sustainable inhaler choices.
The report concludes that integrating environmental considerations into respiratory care can significantly reduce healthcare’s carbon footprint without compromising patient outcomes.
